Please assess the completion status of the following clinical trial:

Trial Title: Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally by Needle or Needle-Free PharmaJet Injector

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* In good health as determined by medical history and physical examination (including blood pressure and heart rate).~* Negative for human immunodeficiency virus-1 (HIV-1) antibodies, Hepatitis C antibodies \& Hepatitis B surface antigen.~* Females negative by urine pregnancy test at screening and immediately prior to injection, and were willing to use reliable means of contraception.~* Body Mass Index (BMI) ≤ 35 kg/m\^2.~Exclusion Criteria:~* Any Grade 2 or above abnormality in the screening laboratory tests.~* History of Dengue Fever, Japanese Encephalitis, West Nile or Yellow Fever disease.~* Seropositivity to dengue or West Nile virus.~* Extensive scarring or tattoo (\> 50%) on arms, shoulders, neck face and head.~* History of significant dermatologic disease in the last 6 months.~* Receipt or planned receipt of any vaccine in the 4 weeks preceding or following the Day 0 or 90 vaccinations.~* Any planned travel to dengue endemic areas including the Caribbean, Mexico, Central America, South America or Southeast Asia, during the study period and during the month prior to screening.~* Use of systemic corticosteroids therapy within the previous 6 months (at a dose of 0.5 mg/kg/day). Topical prednisone is not permitted if currently in use or used within the last month prior to the first vaccination.~* Use of any prescribed medication 7 days before the first injection.~* Previous vaccination in a clinical study or with an approved product against Dengue Fever, Yellow Fever and or Japanese Encephalitis.~* Known or suspected congenital or acquired immunodeficiency or receipt of immunosuppressive therapy in the last 6 months.~* Planned donation of blood during the period of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Group 1: TDV using PharmaJet® Injector (Type: EXPERIMENTAL): Takeda's Tetravalent Dengue Vaccine Candidate (TDV) \[previously DENVax\] one dose injection in arm 1 and placebo: phosphate buffered saline (PBS) one dose injection in arm 2, using needle-free PharmaJet® Injector, intradermal, on Day 0 and TDV, injection using needle-free PharmaJet® Injector, intradermal, one dose on Day 90.
- Group 2: TDV using PharmaJet® Injector (Type: EXPERIMENTAL): TDV injection, one dose in each arm, using needle-free PharmaJet® Injector, intradermal, on Day 0 and placebo: PBS, injection using needle-free PharmaJet® Injector, intradermal, one dose on Day 90.
- Group 3: TDV using Needle and Syringe (Type: EXPERIMENTAL): TDV one dose injection in arm 1 and placebo: PBS one dose injection in arm 2, using needle and syringe, intradermal, on Day 0 and TDV injection using needle and syringe, intradermal, one dose on Day 90.
- Group 4: TDV using PharmaJet® Injector (Type: EXPERIMENTAL): TDV injection, one dose in each arm, using needle-free PharmaJet® Injector, intradermal, on Day 0 and TDV, injection using needle-free PharmaJet® Injector, intradermal, one dose on Day 90.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete